David Aguiar
Overview
Explore the profile of David Aguiar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aguiar D, Ros L, Perez D, Croissier L, Mori M, Hernandez M, et al.
Breast Dis
. 2022 Aug;
41(1):351-361.
PMID: 36031886
Background: High body mass index (BMI) is regarded as a poor prognostic factor in breast cancer (BC). However, its association with pathological complete response (pCR) and survival after neoadjuvant chemotherapy...
2.
Gutierrez L, Royuela A, Carcereny E, Lopez-Castro R, Rodriguez-Abreu D, Massuti B, et al.
BMC Cancer
. 2021 Sep;
21(1):977.
PMID: 34465283
Background: There is a lack of useful diagnostic tools to identify EGFR mutated NSCLC patients with long-term survival. This study develops a prognostic model using real world data to assist...
3.
Provencio M, Terrasa J, Garrido P, Campelo R, Aparisi F, Diz P, et al.
BMC Cancer
. 2021 Mar;
21(1):230.
PMID: 33676426
Background: AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data,...
4.
Nunez-Garcia B, Rodriguez-Pertierra M, Sequero S, Carvajal L, Ruano-Ravina A, Aguiar D, et al.
Hematol Oncol
. 2021 Feb;
39(4):506-512.
PMID: 33528063
Nodular lymphocytic predominance Hodgkin lymphoma (NLPHL) is a very uncommon subtype of Hodgkin lymphoma (HL), representing approximately 5% of all HL cases, with an incidence of 0.3/100,000 cases per year...
5.
Barquin M, Calvo V, Garcia-Garcia F, Nunez B, Sanchez-Herrero E, Serna-Blasco R, et al.
Cancer Epidemiol
. 2020 May;
67:101737.
PMID: 32450544
Background: Biological differences between the sexes have a major impact on disease and treatment outcome. In this paper, we evaluate the prognostic value of sex in stage IV non-small-cell lung...
6.
Conde E, Hernandez S, Martinez R, Angulo B, de Castro J, Collazo-Lorduy A, et al.
J Thorac Oncol
. 2019 Jul;
14(12):2120-2132.
PMID: 31349061
Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support...
7.
Rueda A, Calvo V, Casanova M, Rodriguez-Abreu D, Aguiar D, Llanos M, et al.
Leuk Lymphoma
. 2018 Dec;
60(6):1576-1579.
PMID: 30516082
No abstract available.
8.
Provencio M, Royuela A, Torrente M, Pollan M, Gomez-Codina J, Sabin P, et al.
Cancer
. 2017 Jun;
123(19):3709-3716.
PMID: 28608996
Background: Relatively few studies have analyzed the mortality of follicular lymphoma (FL) patients in comparison with a sex- and age-matched general population. This study analyzed the overall survival (OS) of...
9.
Provencio M, Sabin P, Gomez-Codina J, Torrente M, Calvo V, Llanos M, et al.
PLoS One
. 2017 May;
12(5):e0177204.
PMID: 28493986
Background: Follicular lymphoma is the second most common non-Hodgkin lymphoma in the United States and Europe. However, most of the prospective randomized studies have very little follow-up compared to the...
10.
Montes-Moreno S, Batlle A, Gonzalez de Villambrosia S, Sanchez-Espiridion B, Cereceda L, Gonzalez-Barca E, et al.
Haematologica
. 2014 Apr;
99(8):e138-41.
PMID: 24763400
No abstract available.